Ying Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying Lu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Guang Han
Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
1 shared publication - Guoliang Pi
Department of Radiation Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication Jiangqiong Huang
Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China
1 shared publicationJianping Bi
Department of Radiation Oncology Hubei Cancer Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
1 shared publication- Vivek Verma
Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
1 shared publication - Xiaofang Dai
Cancer Center Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
1 shared publication
Latest Publications
- Open Access
- 3 November 2026
- Published by Wiley in Precision Radiation Oncology
Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy
Objective: Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively investigated to improve clinical outcomes; however, this strategy may also increase the risk of treatment‐related toxicities. This multicenter study aimed to identify clinical and dosimetric predictors of treatment‐related pneumonitis (TRP) in this patient population, focusing on modifiable predictors of toxicity. Methods: A retrospective review was conducted on 69 patients with lung or esophageal cancer treated at three hospitals. All patients received concurrent ICIs, chemotherapy, and thoracic radiotherapy at a dose of 50–60 Gy (in 2 Gy fractions) using inverse‐planned techniques. TRP was graded according to the Common Terminology Criteria for Adverse Events version 5.0. Logistic regression modeling and receiver operating characteristic (ROC) analysis were employed for statistical evaluation. Results: Any‐grade TRP occurred in 56.5% of patients. Grade 2–5 TRP occurred in 30.4%, 8.7%, 1.4%, and 0% of patients, respectively. Age ( p = 0.01; OR = 1.1) and mean lung dose (MLD) ( p = 0.02; OR = 2.4) independently contributed to the risk of any‐grade TRP. Age ( p = 0.03; OR = 1.1) and MLD ( p = 0.04; OR = 1.7) were also identified as risk factors for grade 2+ TRP. Other parameters, such as lung V 5, V 10, V 15, V 20, and V 30 were not significantly associated with TRP. ROC analysis identified 13.6 Gy as the optimal MLD threshold for predicting both any‐grade and grade 2+ TRP. Conclusions: MLD and age were associated with a higher risk of TRP in patients receiving concurrent chemoradiotherapy and ICIs. These findings may help inform revisions to lung dose constraints, although validation in large‐scale prospective trials is warranted.
- 3 November 2026
- Published by Wiley in Precision Radiation Oncology
Open AccessDosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy
Objective: Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively investigated to improve clinical outcomes; however, this strategy may also increase the risk of treatment‐related toxicities. This multicenter study aimed to identify clinical and dosimetric predictors of treatment‐related pneumonitis (TRP) in this patient population, focusing on modifiable predictors of toxicity. Methods: A retrospective review was conducted on 69 patients with lung or esophageal cancer treated at three hospitals. All patients received concurrent ICIs, chemotherapy, and thoracic radiotherapy at a dose of 50–60 Gy (in 2 Gy fractions) using inverse‐planned techniques. TRP was graded according to the Common Terminology Criteria for Adverse Events version 5.0. Logistic regression modeling and receiver operating characteristic (ROC) analysis were employed for statistical evaluation. Results: Any‐grade TRP occurred in 56.5% of patients. Grade 2–5 TRP occurred in 30.4%, 8.7%, 1.4%, and 0% of patients, respectively. Age ( p = 0.01; OR = 1.1) and mean lung dose (MLD) ( p = 0.02; OR = 2.4) independently contributed to the risk of any‐grade TRP. Age ( p = 0.03; OR = 1.1) and MLD ( p = 0.04; OR = 1.7) were also identified as risk factors for grade 2+ TRP. Other parameters, such as lung V 5, V 10, V 15, V 20, and V 30 were not significantly associated with TRP. ROC analysis identified 13.6 Gy as the optimal MLD threshold for predicting both any‐grade and grade 2+ TRP. Conclusions: MLD and age were associated with a higher risk of TRP in patients receiving concurrent chemoradiotherapy and ICIs. These findings may help inform revisions to lung dose constraints, although validation in large‐scale prospective trials is warranted.